Literature DB >> 9012754

Pathogenesis of rheumatoid arthritis.

C M Weyand1, J J Goronzy.   

Abstract

Chronicity and destructive potential are characteristic features of the inflammatory response in the synovial membrane typical for RA. The dominant paradigm has proposed that an exogenous antigen, likely an infectious organism, targets the synovia and elicits a chronic immune response. Support for this disease model has come from describing the cellular components of the inflammatory lesions, which are composed of macrophages, T cells, and B cells. The observation that HLA molecules function by specifically binding antigenic peptides and presenting them to T cells has boosted the concept of an antigen-driven response. The last decade in RA research has been dominated by a shift from premolecular to molecular techniques. A major effort has been made to determine which cytokines and inflammatory mediators are produced at the site of disease. Tissue residing and infiltrating cells secrete proinflammatory cytokines in situ, which likely have a critical role in amplifying and maintaining the inflammation. We are beginning to understand that migration of inflammatory cells into the tissue is an important component of disease, specifically because adhesion molecules not only facilitate tissue infiltration, but also affect cell activation and cell-cell and cell-matrix interactions. The paradigm that RA is an antigen-driven and thus T cell-mediated disease has brought attempts to use T cell-depleting reagents as therapeutics. Although T cells could be eliminated in the peripheral blood, overall therapeutic benefits have been minimal and accompanied by major side effects. The lack of therapeutic efficacy has been demonstrated to be combined with the persistence and the selective proliferation of T cells in the joint, reemphasizing the role of tissue-infiltrating T cells in the disease. Studies of the composition of the T cell infiltrate have demonstrated heterogeneity, indicating that disease-relevant T cells are probably low in frequency. A new perspective on the role of T cells in RA has been opened by studies establishing that RA patients select a unique repertoire of T cells in the thymus and that clonal expansion of CD4 T cells is a frequent event in RA patients. Pathology of T cell function might be much more systemic than suspected so far. RFs remain the major autoantibodies in RA patients. In the last 10 years, it has become clear that they are not exclusively built under pathologic conditions but that RF-expressing B cells are an important element of normal immune responses. All immunoglobulin isotypes are represented among RF molecules. Some of them have accumulated somatic mutations, suggesting the influence of antigen recognition and T cell help. T cell control of RF production may explain the observation that RF positivity is an HLA-dependent phenomenon. Major progress in understanding pathologic events leading to RA can be expected by abandoning single hit models, which are too simplified and underestimate the complexity of the disease. In particular, taking into account that nonimmune tissues and mechanisms might be equally important in pathogenesis will open new avenues of conceptual approaches. Cross-fertilization will likely come from genetic studies aimed at detecting underlying genetic risk factors in common genetic disease. Emerging data indicate that several genetic risk determinants, each of which is nonpathologic if occurring alone, can add up to confer disease risk. One of these genetic elements in RA has been mapped to the HLA region. A sequence polymorphism in the HLA-DR B1 gene appears to be a strong genetic risk factor in several ethnic groups. Correlation of clinical presentation of RA and the inheritance of the RA risk gene suggests that the gene product is not necessary in disease initiation but functions by modulating disease pattern and severity. The next decade in RA research will be dedicated toward unraveling how genetic determinants can introduce pathology (e.g., how HLA genes can function as progre

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9012754     DOI: 10.1016/s0025-7125(05)70504-6

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  39 in total

Review 1.  Dendritic cells, Fc{gamma} receptors, and Toll-like receptors: potential allies in the battle against rheumatoid arthritis.

Authors:  T R D J Radstake; A W T van Lieshout; P L C M van Riel; W B van den Berg; G J Adema
Journal:  Ann Rheum Dis       Date:  2005-05-05       Impact factor: 19.103

2.  HLA-DRB1 frequency in patients with familial and sporadic rheumatoid arthritis in north east of Iran.

Authors:  Massoud Saghafi; Najmeh Nohesara; Houshang Rafatpanah; Jaleh Shariati; Mohamad Taghi Shakeri
Journal:  Clin Rheumatol       Date:  2014-04-24       Impact factor: 2.980

Review 3.  Molecular mechanism of immune response, synovial proliferation and apoptosis in rheumatoid arthritis.

Authors:  T Hasunuma; T Kato; T Kobata; K Nishioka
Journal:  Springer Semin Immunopathol       Date:  1998

Review 4.  Pathogenesis of juvenile chronic arthritis: genetic and environmental factors.

Authors:  K Murray; S D Thompson; D N Glass
Journal:  Arch Dis Child       Date:  1997-12       Impact factor: 3.791

5.  Combined treatment of etanercept and MTX reverses Th1/Th2, Th17/Treg imbalance in patients with rheumatoid arthritis.

Authors:  Chen Lina; Wang Conghua; Leng Nan; Zhu Ping
Journal:  J Clin Immunol       Date:  2011-05-12       Impact factor: 8.317

6.  Peroxisome proliferator-activated receptor-gamma haploinsufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis.

Authors:  K Setoguchi; Y Misaki; Y Terauchi; T Yamauchi; K Kawahata; T Kadowaki; K Yamamoto
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

7.  Anti-inflammatory Effect of Somatostatin Analogue Octreotide on Rheumatoid Arthritis Synoviocytes.

Authors:  Claudia Casnici; Donatella Lattuada; Katia Crotta; Marcello Claudio Truzzi; Costantino Corradini; Francesca Ingegnoli; Noemi Tonna; Fabio Bianco; Ornella Marelli
Journal:  Inflammation       Date:  2018-10       Impact factor: 4.092

8.  TRAIL death receptor-4, decoy receptor-1 and decoy receptor-2 expression on CD8+ T cells correlate with the disease severity in patients with rheumatoid arthritis.

Authors:  Atil Bisgin; Ender Terzioglu; Cigdem Aydin; Burcak Yoldas; Veli Yazisiz; Nilufer Balci; Huseyin Bagci; Reginald M Gorczynski; Cezmi A Akdis; Salih Sanlioglu
Journal:  BMC Musculoskelet Disord       Date:  2010-08-27       Impact factor: 2.362

9.  Heterogeneity of rheumatoid arthritis: from phenotypes to genotypes.

Authors:  C M Weyand; P A Klimiuk; J J Goronzy
Journal:  Springer Semin Immunopathol       Date:  1998

10.  IL-17 induces the production of IL-16 in rheumatoid arthritis.

Authors:  Mi-La Cho; Young Ok Jung; Kyoung-Woon Kim; Mi-Kyung Park; Hye-Joa Oh; Ji-Hyeon Ju; Young-Gyu Cho; Jun-Ki Min; Sung-Il Kim; Sung-Hwan Park; Ho-Youn Kim
Journal:  Exp Mol Med       Date:  2008-04-30       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.